ALS, frontotemporal dementia and limbic-predominant age-related TDP-43 encephalopathy (LATE) look like three separate illnesses. ALS attacks motor neurons and leads to muscle weakness and paralysis. FTD strikes the frontal and temporal lobes, altering language, personality and behavior. LATE progresses slowly and mimics Alzheimer's disease, mostly in people past 85. What ties them together is a protein: TDP-43. A review published August 24 in JAMA Neurology argues that this shared biology deserves more weight than the differing symptoms that have long defined each condition.
The paper, "TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging," was written by a large international group of clinicians and researchers led by Michael Benatar, M.D., Ph.D., the Walter Bradley Chair in ALS Research and Executive Director of the ALS Center at the University of Miami Health System and the Miller School. The authors propose a new umbrella term, TDP-43 associated neurodegenerative disease, or TAND, to capture the relationship among these disorders.
The practical stakes are in how research gets organized. If ALS, FTD and LATE are versions of one underlying protein disease, then biomarkers developed for one may be informative across all of them, and clinical trials could be designed around the biology being targeted rather than the clinical label a patient happens to carry. That kind of reframing has already reshaped Alzheimer's research, where amyloid and tau markers increasingly define who enters a trial.
For patients and families, nothing changes overnight; this is a conceptual framework, not a therapy. But the shift matters for anyone facing a LATE or FTD diagnosis, conditions with far fewer research resources than Alzheimer's. Grouping them with ALS under a single biological heading pools the scientific effort, and the authors expect the effects to reach biomarker development and trial design first, with clinical care following later.